NCI requests $7.8B for FY2023 to increase R01 paylines to 13th percentile

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NCI is asking for an appropriation of $7.8 billion for fiscal year 2023—about $800 million above the House’s FY22 proposed budget for NCI.

This amount, specified by the institute’s Bypass Budget, is calibrated toward raising paylines to the 15th percentile by 2025. 

“Several years ago, we started a concerted effort to raise the payline to the 15th percentile by 2025,” Sharpless said Sept. 1 in his remarks to the National Cancer Advisory Board. “That is the ‘15-by-25’ initiative, and robust and sustained investments are needed to achieve that level.”

As it stands, NCI paylines are at the 11th percentile, and the success rate for investigator-initiated research project grants is 12.8%.

The Bypass Budget, also known as the Professional Judgment Budget, is one of the unique authorities given to NCI under the National Cancer Act of 1971. The law allows the institute director to bypass budget review at NIH and HHS and submit this request directly to the White House. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Matthew Bin Han Ong
Matthew Bin Han Ong
Table of Contents

YOU MAY BE INTERESTED IN

Acting Director Dr. Krzysztof Ptak’s words reverberated throughout the meeting room—and the heads of several of us—during the National Cancer Institute’s Office of Cancer Centers update on the final day of the 2024 Association of American Cancer Institutes/Cancer Center Administrators Forum Annual Meeting in Chicago.
Virginia Commonwealth University has been awarded a five-year, $9 million grant from NCI to establish a pioneering Cancer Control Equity Research Center. This initiative aims to enhance the dissemination and implementation of health promotion and cancer prevention services for individuals and families residing in Virginia’s Housing and Urban Development-administered income-based housing communities in the Greater Richmond region and Hampton Roads.
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
Matthew Bin Han Ong
Matthew Bin Han Ong

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login